Alkermes plc. Dilutive Share Adjustment
Alkermes plc. (ALKS) reported Dilutive Share Adjustment of 6.45 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment · last filed 2026-07-28
- Alkermes plc. weighted average number diluted shares outstanding adjustment for the quarter ending 2026-06-30 was 6.45M shares, a 89.88% increase year-over-year.
- Alkermes plc. weighted average number diluted shares outstanding adjustment for the quarter ending 2025-12-31 was 4.29M shares, a 0.49% increase year-over-year.
- Alkermes plc. weighted average number diluted shares outstanding adjustment for the quarter ending 2025-09-30 was 3.42M shares, a 6.37% decline year-over-year.
- Alkermes plc. weighted average number diluted shares outstanding adjustment for the quarter ending 2025-06-30 was 3.40M shares, a 27.94% increase year-over-year.
- Alkermes plc. weighted average number diluted shares outstanding adjustment for fiscal 2025 was 4.04M shares, a 6.15% increase from fiscal 2024.
- Alkermes plc. weighted average number diluted shares outstanding adjustment for fiscal 2024 was 3.81M shares, a 8.53% increase from fiscal 2023.
- Alkermes plc. weighted average number diluted shares outstanding adjustment for fiscal 2023 was 3.51M shares.
- Alkermes plc. weighted average number diluted shares outstanding adjustment for fiscal 2021 was 3.81M shares.
| Period end | Weighted Average Number Diluted Shares Outstanding Adjustment 3 month | Weighted Average Number Diluted Shares Outstanding Adjustment 6 month | Weighted Average Number Diluted Shares Outstanding Adjustment 9 month | Weighted Average Number Diluted Shares Outstanding Adjustment 12 month |
|---|---|---|---|---|
| 2026-06-30 | 6.45M shares 10-Q · filed 2026-07-28 | |||
| 2025-12-31 | 4.29M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 3.86M shares derived: average of 2 quarters · filed 2026-02-25 | 3.71M shares derived: average of 3 quarters · filed 2026-07-28 | 4.04M shares 10-K · filed 2026-02-25 |
| 2025-09-30 | 3.42M shares 10-Q · filed 2025-10-28 | 3.41M shares derived: average of 2 quarters · filed 2026-07-28 | 3.96M shares 10-Q · filed 2025-10-28 | 4.11M shares derived: average of 4 quarters · filed 2026-07-28 |
| 2025-06-30 | 3.40M shares 10-Q · filed 2026-07-28 | 4.28M shares 10-Q · filed 2026-07-28 | 4.33M shares derived: average of 3 quarters · filed 2026-07-28 | 4.16M shares derived: average of 4 quarters · filed 2026-07-28 |
| 2025-03-31 | 5.33M shares 10-Q · filed 2026-05-05 | 4.80M shares derived: average of 2 quarters · filed 2026-05-05 | 4.42M shares derived: average of 3 quarters · filed 2026-05-05 | 3.98M shares derived: average of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | 4.27M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 3.97M shares derived: average of 2 quarters · filed 2026-02-25 | 3.53M shares derived: average of 3 quarters · filed 2026-02-25 | 3.81M shares 10-K · filed 2026-02-25 |
| 2024-09-30 | 3.66M shares 10-Q · filed 2025-10-28 | 3.16M shares derived: average of 2 quarters · filed 2025-10-28 | 3.65M shares 10-Q · filed 2025-10-28 | 2.60M shares derived: average of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | 2.66M shares 10-Q · filed 2025-07-29 | 3.81M shares 10-Q · filed 2025-07-29 | 2.24M shares derived: average of 3 quarters · filed 2026-02-25 | 3.01M shares derived: average of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | 5.00M shares 10-Q · filed 2025-05-01 | 2.04M shares derived: average of 2 quarters · filed 2026-02-25 | 3.12M shares derived: average of 3 quarters · filed 2026-02-25 | 3.66M shares derived: average of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -927.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 2.18M shares derived: average of 2 quarters · filed 2026-02-25 | 3.21M shares derived: average of 3 quarters · filed 2026-02-25 | 3.51M shares 10-K · filed 2026-02-25 |
| 2023-09-30 | 5.30M shares 10-Q · filed 2024-10-24 | 5.29M shares derived: average of 2 quarters · filed 2024-10-24 | 4.99M shares 10-Q · filed 2024-10-24 | |
| 2023-06-30 | 5.27M shares 10-Q · filed 2024-07-24 | 5.06M shares 10-Q · filed 2024-07-24 | ||
| 2021-12-31 | 3.81M shares 10-K · filed 2024-02-21 | |||
| 2021-06-30 | 3.12M shares 10-Q · filed 2022-07-27 | |||
| 2013-06-30 | 8.77M shares 10-Q · filed 2013-07-25 | 7.64M shares derived: average of 2 quarters · filed 2013-07-25 | 6.89M shares derived: average of 3 quarters · filed 2013-07-25 | 6.46M shares derived: average of 4 quarters · filed 2013-07-25 |
| 2013-03-31 | 6.51M shares derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-23 | 5.95M shares derived: average of 2 quarters · filed 2013-05-23 | 5.69M shares derived: average of 3 quarters · filed 2013-05-23 | 5.39M shares 10-K · filed 2013-05-23 |
| 2012-12-31 | 5.40M shares 10-Q · filed 2013-01-31 | 5.28M shares derived: average of 2 quarters · filed 2013-01-31 | 5.01M shares 10-Q · filed 2013-01-31 | |
| 2012-09-30 | 5.16M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2012-11-01 | 4.84M shares 10-Q · filed 2012-11-01 | ||
| 2012-06-30 | 4.51M shares 10-Q · filed 2013-07-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |